Solriamfetol

Solriamfetol, also known by its chemical name as a selective dopamine and norepinephrine reuptake inhibitor, is a prescription medication developed to promote wakefulness. It is primarily used to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).

Approved by the U.S. Food and Drug Administration (FDA) in 2019, solriamfetol is marketed under the brand name Sunosi. It functions by increasing the levels of dopamine and norepinephrine in the brain, which are neurotransmitters involved in wakefulness and alertness. Its mechanism of action is distinct from stimulants like amphetamines, providing a potentially lower risk of abuse and dependence.

The medication is typically administered once daily, with dosage adjusted based on individual response and tolerability. Common side effects include headache, nausea, decreased appetite, increased blood pressure, and insomnia. Serious adverse effects are rare but may include hypertensive episodes or increased heart rate.

Solriamfetol is contraindicated in individuals with a history of hypersensitivity to the drug or those with concomitant use of monoamine oxidase inhibitors (MAOIs). Caution is advised when prescribing to patients with cardiovascular conditions or hypertension.

As with other wakefulness-promoting agents, solriamfetol should be used as part of a comprehensive management plan for sleep disorders, including behavioral strategies and treatment of underlying conditions. Its approval provides an additional option for patients experiencing excessive sleepiness, with ongoing research evaluating its long-term safety and efficacy.